High
--
Open
--
VWAP
--
Vol
--
Mkt Cap
--
Low
--
Amount
--
EV/EBITDA(TTM)
--
Total Shares
--
EV
--
EV/OCF(TTM)
--
P/S(TTM)
--
Market Estimates
Earnings Estimates
Revenue
YoY Chg
EPS
YoYChg
FY2025Q4
FY2026Q1
FY2026Q2
560.00
-88.8%
-0.247
-25.11%
1,000
-80%
-0.276
+6.15%
1,000
-80%
-0.290
+7.41%
Estimates Revision
The market is revising No Change the revenue expectations for Altimmune, Inc. (ALT) for FY2025, with the revenue forecasts being adjusted by 0% over the past three months. During the same period, the stock price has changed by 40.48%.
Revenue Estimates for FY2025
No Change
0.00%
In Past 3 Month
EPS Estimates for FY2025
No Change
0.00%
In Past 3 Month
Stock Price
Go Up
+40.48%
In Past 3 Month
3 Analyst Rating
Wall Street analysts forecast ALT stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for ALT is 13.00 USD with a low forecast of 12.00 USD and a high forecast of 14.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
2 Buy
1 Hold
0 Sell
Moderate Buy
Current: 5.310
Low
12.00
Averages
13.00
High
14.00
Current: 5.310
Low
12.00
Averages
13.00
High
14.00
Citizens JMP
Jonathan Wolleben
Outperform
to
Outperform
downgrade
$15 -> $14
2025-11-07
Reason
Citizens JMP
Jonathan Wolleben
Price Target
$15 -> $14
2025-11-07
downgrade
Outperform
to
Outperform
Reason
Citizens JMP analyst Jonathan Wolleben lowered the firm's price target on Altimmune to $14 from $15 and keeps an Outperform rating on the shares. The firm says it looks forward to the oral late-breaking presentation of pemvidutide's Phase 2b data at the Liver Meeting with 48-week data on track for this quarter.
UBS
Buy
downgrade
$26 -> $24
2025-08-13
Reason
UBS
Price Target
$26 -> $24
2025-08-13
downgrade
Buy
Reason
UBS lowered the firm's price target on Altimmune to $24 from $26 and keeps a Buy rating on the shares. Despite the IMPACT Phase 2b trial setback, UBS still sees a sizeable opportunity for pemvidutide in nonalcoholic steatohepatitis, the analyst tells investors in a research note.
Goldman Sachs
initiated
$1
2025-07-10
Reason
Goldman Sachs
Price Target
$1
2025-07-10
initiated
Reason
Goldman Sachs resumed coverage of Altimmune with a Sell rating and $1 price target, representing 79% downside. The company's data to-date has not demonstrated a meaningfully differentiated profile for pemvidutide in either obesity or metabolic dysfunction associated steatohepatitis, the analyst tells investors in a research note. The firm sees challenges for Altimmune to execute the full clinical development program required to bring pemvidutide to market.
Citizens JMP
Outperform
to
NULL
downgrade
$25 -> $15
2025-07-10
Reason
Citizens JMP
Price Target
$25 -> $15
2025-07-10
downgrade
Outperform
to
NULL
Reason
Citizens JMP lowered the firm's price target on Altimmune to $15 from $25 and keeps an Outperform rating on the shares. Pemvidutide is still a competitive MASH candidate, but its path forward has become more difficult, the analyst tells investors in a research note. The firm thinks pemvidutide will hit both fibrosis and MASH resolution in Phase 3, but says Altimmune needs additional capital to get through the pivotal MASH program, which will now be the overhang on the stock.
Jefferies
Buy
maintain
$28
2025-06-27
Reason
Jefferies
Price Target
$28
2025-06-27
maintain
Buy
Reason
Jefferies believes Altimmune stock dropping 50% after the company announced results from its IMPACT study is overkill, as data met the firm's most likely scenario. Jefferies sees pemvidutide as a viable/safe drug uniquely positioned in MASH as the first incretin to hit statistical significance on histology at 24 weeks with potential to deepen with time and thinks these factors differentiate the drug from the fibroblast growth factor 21 class, the firm told investors in a research note. Jefferies added that the company can take meaningful share in the growing MASH market if successful. The firm reiterated a Buy rating and $28 price target on shares.
H.C. Wainwright
Patrick Trucchio
Buy
maintain
$12
2025-06-26
Reason
H.C. Wainwright
Patrick Trucchio
Price Target
$12
2025-06-26
maintain
Buy
Reason
See All Ratings
Valuation Metrics
The current forward P/E ratio for Altimmune Inc (ALT.O) is -4.68, compared to its 5-year average forward P/E of -5.72. For a more detailed relative valuation and DCF analysis to assess Altimmune Inc 's fair value, click here.
Forward PE
The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.
N/A
5Y Average PE
-5.72
Current PE
-4.68
Overvalued PE
-2.75
Undervalued PE
-8.69
Forward EV/EBITDA
The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.
N/A
5Y Average EV/EBITDA
-2.72
Current EV/EBITDA
0.00
Overvalued EV/EBITDA
-0.85
Undervalued EV/EBITDA
-4.58
Forward PS
The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.
N/A
5Y Average PS
26495.43
Current PS
0.00
Overvalued PS
78113.92
Undervalued PS
-25123.07
Financials
Annual
Quarterly
N/A
Total Revenue
N/A
Operating Profit
N/A
Net Income after Tax
N/A
EPS - Diluted
N/A
Free Cash Flow
N/A
Gross Profit Margin - %
N/A
FCF Margin - %
N/A
Net Margin - %
Trading Trends
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Hedge Fund
Hedge Funds are Neutral. There are no significant trading trends over the last quarter.
Sold
Bought
Congress Trading
Congress are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
Bought
ALT News & Events
Events Timeline
(ET)
2025-12-02
16:10:00
ALT 5 Sigma Faces Nasdaq Compliance Issue Due to Delay in 10-Q Filing
2025-12-01 (ET)
2025-12-01
07:40:00
Altimmune Announces CEO Succession Plan with Garg Stepping Down in 2026
2025-11-11 (ET)
2025-11-11
08:54:14
Altimmune Reveals Results from IMPACT Phase 2b Trial Publication
Sign Up For More Events
Sign Up For More Events
News
![[object Object]](https://d5bp8bijhhba2.cloudfront.net/image/cover_image/2af65b376484ad49f7c62d7b5e7f9077dbbff6fde1f407cfb35a198d4041c235.jpg)
Preview
5.0
12-01NASDAQ.COMAltimmune CEO Vipin Garg Resigns; Pre-Market Stock Declines
![[object Object]](https://d5bp8bijhhba2.cloudfront.net/image/cover_image/2250849d7ce3d95da47316fa622c6d32b515162eb0e3c904faeabb654406d7a0.png)
Preview
5.0
12-01SeekingAlphaAltimmune Reveals Change in CEO Leadership
![[object Object]](https://d5bp8bijhhba2.cloudfront.net/image/cover_image/81c3f099a8b835ce8cfe448273f78f5af42b328de102f07cdad880f8185b6664.jpg)
Preview
6.5
11-25NASDAQ.COMWall Street Analysts Forecast a 250.59% Increase for Altimmune (ALT): Key Insights to Consider
Sign Up For More News
People Also Watch
FAQ
What is Altimmune Inc (ALT) stock price today?
What is Altimmune Inc (ALT)'s business?
What is the price predicton of ALT Stock?
What is Altimmune Inc (ALT)'s revenue for the last quarter?
What is Altimmune Inc (ALT)'s earnings per share (EPS) for the last quarter?
What changes have occurred in the market's expectations for Altimmune Inc (ALT)'s fundamentals?
How many employees does Altimmune Inc (ALT). have?